In his October 7, 2026 Forbes article, “The Next Big Health Crisis May Be Hiding in Your Liver,” Dr. Peter Ubel highlights the growing public health threat of metabolic dysfunction–associated steatotic liver disease (MASLD), commonly known as fatty liver disease. Affecting roughly one in three adults worldwide, MASLD is closely associated with obesity, type 2 diabetes, insulin resistance, and physical inactivity.
The danger is that fatty liver disease often develops silently, with few or no symptoms until significant liver damage has occurred. Over time, it can progress from fat accumulation to inflammation, fibrosis, cirrhosis, and even liver cancer. MASLD is also associated with increased cardiovascular risk.
The central message is that early identification and intervention are essential. Blood tests, fibrosis risk assessments, and appropriate imaging can help identify patients before irreversible damage develops. Weight management, healthier eating, regular exercise, and improved metabolic health can prevent or slow disease progression.
Bottom line: Fatty liver disease is a widespread, frequently overlooked condition that could become a major driver of liver-related illness and healthcare costs. Earlier detection offers an opportunity to prevent serious complications rather than treat them after they develop.
asf